News | June 04, 2007

Heart Patch Helps Damaged Cardiac Tissue Heal

June 5, 2007 — A patch designed to help damaged cardiac tissue recover from a heart attack has been successful in early animal testing and is moving toward potential human use, researchers report.

"It is a biodegradable, porous polyurethane scaffold that is placed atop the infarcted [damaged] region of the heart," explained study author William R. Wagner, a professor of surgery and bioengineering at the University of Pittsburgh. "It changes the environment during the remodeling process, and degrades over several months. The impact of it is to have a thicker heart wall."

His group reports on the patch in the June 12 issue of the Journal of the American College of Cardiology.

In a trial with rats that had induced heart attacks, the patch was implanted directly on the damaged part of the heart wall. The wall was thicker, "with abundant smooth muscle bundles," and healthier, mature heart cells, the researchers reported.

The patch is not designed to help produce new, contracting cells in the damaged part of the heart, Wagner stressed. Researchers at other institutions are working toward that goal, he said, "but our patch is more like a biodegradable girdle that changes the way the heart feels through a mechanical effect."

One advantage of the approach is that it could lead to quicker use of the technology in humans, Wagner said.

"It doesn't contain any cells that require attention from a regulatory perspective," he said. "We can suture it onto the heart, which allows a minimally invasive approach."

When and if the technology is used in humans, the patch will be implanted about two weeks after a heart attack, Wagner said. "That's when the heart becomes more symptomatic," he added.

A next step toward human use has started in a trial with pigs, a larger animal whose responses are more similar to those of people, Wagner said.

"We hope to complete the pig study this year," he said. "If then we are looking at positive results in this larger animal, it would mean we could do a clinical trial."

"We haven't paired up with a company yet," but such a commercial partnership would be necessary to bring the technology to market, Wagner said.

"From a theoretical perspective, it is reasonable to believe that it will work," he said. "It would alter the healing response so that the heart wall would not thin out and would have mechanical properties that preserve its function."

For more information visit: www.AmericanHeart.org

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init